Xu Xiaochun, Tichauer Kenneth M, Samkoe Kimberley S
Surgery-Research, Dartmouth-Hitchcock Medical Center, Lebanon, NH 03756.
Biomedical Engineering, Illinois Institute of Technology, Chicago, IL 60616.
Proc SPIE Int Soc Opt Eng. 2020 Feb;11219. Epub 2020 Feb 19.
Long-term survival of head and neck squamous cell carcinoma (HNSCC) patients have proven to be correlated with negative surgical margins. Paired-Agent Imaging for Resection during Surgery (PAIRS) is capable of drawing the fine line between tumor and normal tissue by employing a control imaging-agent, which is co-administered with the targeted imaging agent to account for nonspecific signal. PAI is highly dependent on the parallel paired-agent delivery and static quantum yield of the agent to trace the molecular concentration. However, it is well known that nonspecific binding of fluorescence probes to plasma proteins can change its delivery, dissociation constant, and quantum yield. A thorough evaluation of the effect of plasma protein binding in the estimation of receptor concentration was performed for the paired-agents in this study. We are planning to evaluate ABY-029, an anti-epithelial growth factor receptor (EGFR) Affibody, and IRDye 700DX as a control agent. The plasma-dependent change in fluorescence intensity, percent binding, and distribution kinetics will be studied for each agent alone, and in combination. In this proceeding, the absorption, emission patterns for the targeted agent, ABY-029, measured by UV-Vis, fluorometer, and Pearl were shown. Initial studies indicate that binding to Bovine serum albumin (BSA), human serum albumin (HSA) and EGFR can introduce the Solvatochromic shift, which will change the absorption and emission pattern for ABY-029. Computational modeling will be performed to determine how each of these changes will affect the determined BP, and thus detection of tumors from normal tissue.
头颈鳞状细胞癌(HNSCC)患者的长期生存已被证明与手术切缘阴性相关。术中切除配对试剂成像(PAIRS)能够通过使用一种对照成像剂来区分肿瘤组织和正常组织,该对照成像剂与靶向成像剂共同给药以解释非特异性信号。PAI高度依赖于平行的配对试剂递送和试剂的静态量子产率来追踪分子浓度。然而,众所周知,荧光探针与血浆蛋白的非特异性结合会改变其递送、解离常数和量子产率。本研究对配对试剂在受体浓度估计中血浆蛋白结合的影响进行了全面评估。我们计划评估一种抗表皮生长因子受体(EGFR)亲和体ABY - 029,并将IRDye 700DX作为对照试剂。将分别研究每种试剂单独以及联合使用时荧光强度、结合百分比和分布动力学的血浆依赖性变化。在此过程中,展示了通过紫外可见分光光度计、荧光计和Pearl测量的靶向试剂ABY - 029的吸收、发射模式。初步研究表明,与牛血清白蛋白(BSA)、人血清白蛋白(HSA)和EGFR的结合会引起溶剂化显色位移,这将改变ABY - 029的吸收和发射模式。将进行计算建模以确定这些变化中的每一个将如何影响所确定的BP,从而实现从正常组织中检测肿瘤。